Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Price-to-Owner-Earnings : 90.30 (As of May. 12, 2024)

View and export this data going back to . Start your Free Trial

What is Swedish Orphan Biovitrum AB Price-to-Owner-Earnings?

As of today (2024-05-12), Swedish Orphan Biovitrum AB's share price is $24.38. Swedish Orphan Biovitrum AB's Owner Earnings per Share (TTM) ended in Mar. 2024 was $0.27. It's Price-to-Owner-Earnings for today is 90.30.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Price-to-Owner-Earnings or its related term are showing as below:

SWTUY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 14.49 Med: 37.25 Max: 1229.95
Current: 42.23

During the past 13 years, the highest Price-to-Owner-Earnings of Swedish Orphan Biovitrum AB was 1229.95. The lowest was 14.49. And the median was 37.25.

SWTUY's Price-to-Owner-Earnings is ranked worse than
68.97% of 419 companies
in the Drug Manufacturers industry
Industry Median: 27.85 vs SWTUY: 42.23

As of today (2024-05-12), Swedish Orphan Biovitrum AB's share price is $24.38. Swedish Orphan Biovitrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Swedish Orphan Biovitrum AB's PE Ratio for today is N/A.

As of today (2024-05-12), Swedish Orphan Biovitrum AB's share price is $24.38. Swedish Orphan Biovitrum AB's EPS without NRI for the trailing twelve months (TTM) ended in was $0.00. Therefore, Swedish Orphan Biovitrum AB's PE Ratio without NRI for today is N/A.

During the past 13 years, Swedish Orphan Biovitrum AB's highest PE Ratio without NRI was 622.46. The lowest was 11.96. And the median was 24.05.

Swedish Orphan Biovitrum AB Price-to-Owner-Earnings Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Price-to-Owner-Earnings Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Owner-Earnings

Get a 7-Day Free Trial

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Owner-Earnings	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Swedish Orphan Biovitrum AB's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Price-to-Owner-Earnings falls into.

Swedish Orphan Biovitrum AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Swedish Orphan Biovitrum AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	24.38	/	0.27
	=	90.30

Swedish Orphan Biovitrum AB (OTCPK:SWTUY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Swedish Orphan Biovitrum AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWTUY) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).